Is AC Immune S.A. (ACIU) a Buy, Sell, or Hold?
AC Immune S.A.
NASDAQ:ACIU
$2.41 USD
-$0.04 (-1.63%)
- Volume
- 164.96K
- Average Volume
- 283.98K
- Market Capitalization
- $245.27M
- P/E Ratio
- -2.95
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $4.00
- Year Low
- $2.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.87
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Andrea Pfeifer |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ACIU |
| CUSIP | H00263105 |
| CIK | 0001651625 |
| Web | https://www.acimmune.com |
| Phone | 41 21 345 91 21 |
| Currency | USD |
| Employees | 122 |
| Country | CH |
Liquidity
| Debt-to-Equity Ratio | 0.14 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.87 |
| Quick Ratio | 0.87 |
| Cash Ratio | 0.21 |
Sales & Book Value
| Annual Sales | $3.57M |
| Price / Sales | 53.59 |
| Cash Flow | -0.52 |
| Price / Cash Flow | -3.90 |
| Price / Book | 6.10 |
Price Target and Rating
| Average Stock Price Forecast | $7.00 |
| High Stock Price Forecast | $7.00 |
| Low Stock Price Forecast | $7.00 |
| Forecast Upside/Downside | -65.57% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.7 |
| Trailing P/E Ratio | -2.95 |
| PEG Ratio | 0.07 |
| P/E Growth | 0.07 |
| Net Income | $-70.45M |
| Net Margin | -1788.79% |
| Pretax Margin | -1788.79% |
| Return on Equity | -123.98% |
| Return on Assets | -48.19% |
Financials Score
| AltmanZ Score | -5.13 |
| Piotroski Score | 2.00 |
| Working Capital | -12.2M |
| Total Assets | 137.42M |
| Ebit | -66.06M |
| Market Cap | 203.11M |
| Total Liabilities | 105.89M |
Poll Results
About AC Immune S.A. (NASDAQ:ACIU) Stock
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candida ... te, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
2026-07-07 07:00:00
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference® 2026, taking place July 12-15 in London, UK. Across these AAIC presentations, we are showing how AC Immune's Morphomer®-based small molecule approach has generated differentiated therapeutic and imaging assets.
2026-06-30 07:00:00
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer's disease (AD) cohorts in ABATE Anti-Abeta antibody dose-response demonstrated with antibodies detected at all dose levels in cohorts AD1-3 Ongoing AD4 cohort includes additional adjuvant designed to enhance ACI-24 responses Lausanne, Switzerland, June 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2 & AD3) of 74 patients with prodromal Alzheimer's disease (AD) in the Phase 1b/2 ABATE trial following 12 months of treatment with ACI-24 anti-amyloid beta (Abeta) active immunotherapy. In the trial to date, ACI-24 has been generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema (ARIA-E).
2026-06-11 07:00:00
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years Final data from Part 1 of VacSYn trial expected in H2 2026 Lausanne, Switzerland, June 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will receive a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, AC Immune's anti-alpha-synuclein (a-syn) active immunotherapy, in early Parkinson's disease (PD).
AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-06-03 10:56:18
AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2026-05-22 07:00:00
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS) Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD) Underlines potential for precision medicine enabling early diagnosis and intervention in multiple neurodegenerative diseases Lausanne, Switzerland, May 22, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography (PET) tracer ACI-19626 showing increased uptake in the brains of patients with amyotrophic lateral sclerosis (ALS). The results presented at the 2026 TDP43 Summit in Madison, Wisconsin, demonstrate that PET scans with ACI-19626 showed tracer uptake significantly higher in key regions of the brain in patients with ALS compared to healthy controls.
2026-05-15 07:01:00
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
2026-05-14 10:55:42
AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
2026-05-12 07:00:00
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appointed interim CEO Dr Pfeifer to serve as an Advisor and Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board Company well-positioned to drive short- and long-term value creation via its wholly-owned pipeline and strategic partnerships Robust balance sheet following recently achieved milestones, with multiple further near-term value-inflection milestones Lausanne, Switzerland, 12 May 2026 -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces that Dr Andrea Pfeifer has decided to retire from her role as Chief Executive Officer (CEO) of AC Immune at the upcoming Annual General Meeting (AGM) to spend more time with her family. AC Immune's Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.
Frequently Asked Questions
-
What is the current AC Immune S.A. (ACIU) stock price?
-
AC Immune S.A.(NASDAQ:ACIU) stock price is $2.41 in the last trading session. During the trading session, ACIU stock reached the peak price of $4 while $2 was the lowest point it dropped to. The percentage change in ACIU stock occurred in the recent session was --1.63% while the dollar amount for the price change in ACIU stock was -$-0.04.
-
ACIU's industry and sector of operation?
-
The NASDAQ listed ACIU is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ACIU?
-
Martin Zugel | Interim CEO & Chairman of the Board
Julien Rongere | Senior Vice President of Regulatory Affairs & Quality Assurance
Matthias Maurer | Senior Vice President & General Counsel
Mark Danton | Executive Vice President of Information Systems & Artificial Intelligence
Günther Staffler | Executive Vice President of Development -
How many employees does ACIU have?
-
Number of ACIU employees currently stands at 122. ACIU operates from Building B, Lausanne, VD 1015, CH.
-
Link for ACIU official website?
-
Official Website of ACIU is: https://www.acimmune.com
-
How do I contact ACIU?
-
ACIU could be contacted at phone #41 21 345 91 21 and can also be accessed through its website. ACIU operates from Building B, Lausanne, VD 1015, CH.
-
How many shares of ACIU are traded daily?
-
The average number of ACIU shares traded daily for last 3 months was 283.98K.
-
What is the market cap of ACIU currently?
-
The market value of ACIU currently stands at $245.27M with its latest stock price at $2.41